Investors In Life Sciences And Beyond
In 2003 the human genome project was completed at a cost of more than $2 billion. In 2008 the cost of sequencing the human genome dropped to $10 million. Today, that cost is falling below $1,000. This is a revolution that will change all of our lives.
Just as the printing press ushered in the Renaissance, Bessemer steel enabled the Industrial Revolution, or the microprocessor is driving our economy today, biotechnology will transform our future. We are investing in the opportunities driven by the dynamic changes and disruptions occurring in life sciences and other technology driven markets.
THE VC23 MISSION
Our mission is to discover and invest in early stage technology companies that have the potential to deliver extraordinary returns on the capital we invest. We strive to be a trusted investor and advisor to our portfolio companies and our investors.
THE VC23 INVESTMENT PRINCIPLES
We seek early-stage companies and management teams with breakthrough technologies and robust intellectual property that creates a sustainable competitive advantage. We concentrate in biotechnology but also have interest in other technology fields. The strength of the management team is of paramount importance to us.
We are versatile and collaborative, and will lead capital rounds or join existing rounds as a smaller participant. Whenever possible, we seek to co-invest with other VC firms or early stage investors.